PRAME 300-309
ALYVDSLFFL cancer vaccine epitope
10 Amino Acids · MW: 1166.3
Amino Acids
10
Molecular Weight
1166.3
Half-life
<1 h
Research Score
4.3
Studies
82
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is PRAME 300-309?
An HLA-A2-restricted epitope from the PRAME tumor antigen. It is studied as a target for peptide vaccination and T-cell receptor-based anti-tumor therapies.
Key Benefits & Mechanisms
immune targeting
TCR recognition
tumor-associated antigen
Research Summary
PRAME is a prominent cancer-testis antigen with broad interest in leukemia and solid tumors. The ALYVDSLFFL epitope is used to measure or induce antigen-specific T-cell activity in cancer research.
Related Peptides
GV1001
Human telomerase reverse transcriptase (hTERT) 611-626 peptide GV1001
A telomerase-derived 16-mer peptide developed as a cancer vaccine antigen. It is designed to trigger T-cell responses against hTERT-expressing tumors.
Cancer ResearchNelipepimut-S
HER2/neu-derived peptide vaccine Nelipepimut-S (E75; KIFGSLAFL)
A 9-mer HLA-A2/A3-restricted peptide from HER2/neu used as a vaccine antigen. It aims to expand cytotoxic T-cell responses against HER2-positive tumors.
Cancer ResearchWT1 peptide
Wilms tumor 1 (WT1) antigen-derived peptide RMFPNAPYL
A WT1-derived 9-mer peptide used in peptide-vaccine strategies for leukemias and solid tumors. It is intended to generate HLA-restricted cytotoxic T-cell responses against WT1-positive cancer cells.
Cancer ResearchSurvivin 2B peptide
Survivin 2B peptide (LMLGEFLKL)
A survivin-derived HLA-A24-restricted epitope investigated as a peptide vaccine antigen. It targets survivin, a frequently overexpressed inhibitor of apoptosis in tumors.
Cancer Research